Pleiotropic Role of Dietary Phytochemicals in Cancer: Emerging Perspectives for Combinational Therapy

REFERENCES

• Sak K: Chemotherapy and dietary phytochemical agents. Chemotherapy Research and Practice 2012, 282570, 2012.
   PubMedGoogle Scholar
• Liu FS: Mechanisms of chemotherapeutic drug resistance in cancer therapy—a quick review. Taiwanese Journal of Obstetrics and Gynecology 48, 239–244, 2009.
   PubMed Web of Science ®Google Scholar
• González-Vallinas M, González-Castejón M, Rodríguez-Casado A, and de Molina AR. Dietary phytochemicals in cancer prevention and therapy: a complementary approach with promising perspectives. Nutr Rev 71, 585–599, 2013.
   PubMed Web of Science ®Google Scholar
• Osiecki H: Cancer: A Nutritional, Biochemical Approach (2nd ed.). Queensland, Australia: Bioconcepts Publishing, 2002.
   Google Scholar
• Liu RH: Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr 134, 3479S–3485S, 2004.
   PubMed Web of Science ®Google Scholar
• Landis-Piwowar KR and Iyer NR: Cancer chemoprevention: current state of the art. Cancer Growth and Metastasis 7, 19–25, 2014.
   PubMedGoogle Scholar
• Alberts DS and Hess LM: Fundamentals of Cancer Prevention. New York: Springer Verlag, 2008.
   Google Scholar
• Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144, 646–674, 2011.
   PubMed Web of Science ®Google Scholar
• Kroemer G and Pouyssegur J: Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13, 472–482, 2008.
   PubMed Web of Science ®Google Scholar
• Manson MM, Foreman BE, Howells LM, and Moiseeva EP: Determining the efficacy of dietary phytochemicals in cancer prevention. Biochemical Society Transactions 35, 1358–1363, 2007.
   PubMed Web of Science ®Google Scholar
• Signorelli P and Ghidoni R: Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem 16, 449–466, 2005.
   PubMed Web of Science ®Google Scholar
• Bravo L: Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev 56, 317–333, 1998.
   PubMed Web of Science ®Google Scholar
• Manson MM: Cancer prevention—the potential for diet to modulate molecular signalling. Trends Mol Med 9, 11–18, 2003.
   PubMed Web of Science ®Google Scholar
• Manach C, Scalbert A, Morand C, Remesy C, and Jimenez L: Polyphenols: food sources and bioavailability. Am J Clin Nutr 79, 727–747, 2004.
   PubMed Web of Science ®Google Scholar
• Araujo JR, Goncalves P, and Martel F: Chemopreventive effect of dietary polyphenols in colorectal cancer cell lines. Nutr Res 31, 77–87, 2011.
   PubMed Web of Science ®Google Scholar
• Khan N and Mukhtar H: Tea and health: studies in humans. Curr Pharm Res 19, 6141–6147, 2013.
   PubMed Web of Science ®Google Scholar
• Ramos S: Cancer chemoprevention and chemotherapy: dietary polyphenols and signaling pathways. Mol Nutr Food Res 52, 507–526, 2008.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay I, Biswas K, Bandyopadhyay U, and Banerjee RK: Turmeric and curcumin: Biological actions and medicinal applications. Curr Sci 87, 44–50, 2004.
   Web of Science ®Google Scholar
• Aggarwal BB, Sundaram C, Malani N, and Ichikawa H: Curcumin: the Indian solid gold. Adv Exp Med Biol 595, 1–75, 2007.
   PubMed Web of Science ®Google Scholar
• Goel A and Aggarwal BB: Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 62, 919–930, 2010.
   PubMed Web of Science ®Google Scholar
• Fathima DN: Curcumin-role in cancer. J Pharm Sci Res 6, 351–355, 2014.
   Google Scholar
• Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, et al.: Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep 28, 1937–1955, 2011.
   PubMed Web of Science ®Google Scholar
• Ikezaki S, Nishikawa A, Furukawa F, Kudo K, Nakamura H, et al.: Chemopreventive effects curcumin on glandular stomach carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine and sodium chloride in rats. Anticancer Res 2001 21, 3407–3411 2001.
   PubMed Web of Science ®Google Scholar
• Lim YP, Lim TT, Chan YL, Song AC, Yeo BH, et al.: The p53 knowledgebase: an integrated information resource for p53 research. Oncogene 26, 1517–1521, 2007.
   PubMed Web of Science ®Google Scholar
• Facchini LM and Penn LZ: The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J 12, 633–651, 1998.
   PubMed Web of Science ®Google Scholar
• Athar M, Back JH, Tang X, Kim KH, Kopelovich L, et al.: Resveratrol: a review of preclinical studies for human cancer prevention. Toxicology and Applied Pharmacology 224, 274–283, 2007.
   PubMed Web of Science ®Google Scholar
• Renaud S and de Lorgeril M: Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339, 1523–1526, 1992.
   PubMed Web of Science ®Google Scholar
• Gupta SC, Kannappan R, Reuter S, Kim JH, and Aggarwal BB: Chemosensitization of tumors by resveratrol. Annals of the NewYork Academy of Sciences 1215, 150–160, 2011.
   PubMed Web of Science ®Google Scholar
• Vanamala J, Reddivari L, Radhakrishnan S, and Travel C: Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/ Wnt and activation of p53 signaling pathways. BMC Cancer 10, 238, 2010.
   PubMed Web of Science ®Google Scholar
• Murakami A, Matsumoto K, Koshimizu K, and Ohigashi H: Effects of selected food factors with chemopreventive properties on combined lipopolysaccharide- and interferon-gamma induced IkappaB degradation in RAW264.7 macrophages. Cancer Lett 195, 17–25, 2003.
   PubMed Web of Science ®Google Scholar
• Garvin S, Ollinger K, and Dabrosin C: Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 231, 113–122, 2006.
   PubMed Web of Science ®Google Scholar
• Kalra N, Roy P, Prasad S, and Shukla Y: Resveratrol induces apoptosis involving mitochondrial pathways in mouse skin tumorigenesis. Life Sci 82, 348–358, 2008.
   PubMed Web of Science ®Google Scholar
• Benitez DA, Hermoso MA, Pozo-Guisado E, Fernandez-Salguero PM, and Castellon EA: Regulation of cell survival by resveratrol involves inhibition of NF kappa B-regulated gene expression in prostate cancer cells. Prostate 69, 1045–1054, 2009.
   PubMed Web of Science ®Google Scholar
• Csaki C, Mobasheri A, and Shakibaei M: Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB mediated inflammation and apoptosis. Arthritis Res Ther 11, R165, 2009.
   PubMed Web of Science ®Google Scholar
• Roy P, Madan E, Kalra N, Nigam N, George J, et al.: Resveratrol enhances ultraviolet B-induced cell death through nuclear factor-kappaB pathway in human epidermoid carcinoma A431 cells. Biochem Biophys Res Commun 384, 215–220, 2009.
   PubMed Web of Science ®Google Scholar
• Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, et al.: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218–220, 1997.
   PubMed Web of Science ®Google Scholar
• Afaq F, Adhami VM, and Ahmad N: Prevention of short-term ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless mice. Toxicol Appl Pharmacol 186, 28–37, 2003.
   PubMed Web of Science ®Google Scholar
• Reagan-Shaw S, Nihal M, and Ahmad N: Dose translation from animal to human studies revisited. FASEB J 22, 659–661, 2008.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Bueso-Ramos C, and Aggarwal BB: Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 62, 4945–4954, 2002.
   PubMed Web of Science ®Google Scholar
• Chatterjee M, Das S, Janarthan M, and Ramachandran HK: Role of 5-lipoxygenase in resveratrol mediated suppression of 7,12-dimethylbenz(alpha)anthracene-induced mammary carcinogenesis in rats. Eur J Pharmacol 668, 99–106, 2011.
   PubMed Web of Science ®Google Scholar
• Whitsett T, Carpenter M, and Lamartiniere CA: Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. J Carcinogenesis 5, 15, 2006.
   Google Scholar
• Tessitore L, Davit A, Sarotto I, and Caderni G: Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis 21, 1619–1622, 2000.
   PubMed Web of Science ®Google Scholar
• Sengottuvelan M, Deeptha K, and Nalini N: Influence of dietary resveratrol on early and late molecular markers of 1,2-dimethylhydrazine-induced colon carcinogenesis. Nutrition 25, 1169–1176, 2009.
   PubMed Web of Science ®Google Scholar
• Yang K, Popova NV, Yang WC, Lozonschi I, Tadesse S, et al.: Interaction of Muc2 and Apc on Wnt signaling and in intestinal tumorigenesis: potential role of chronic inflammation. Cancer Res 68, 7313–7322, 2008.
   PubMed Web of Science ®Google Scholar
• Alfaras I, Juan ME, and Planas JM: trans-Resveratrol reduces precancerous colonic lesions in dimethylhydrazine-treated rats. J Agric Food Chem 58, 8104–8110, 2010.
   PubMed Web of Science ®Google Scholar
• Rajasekaran D, Elavarasan J, Sivalingam M, Ganapathy E, Kumar A, et al.: Resveratrol interferes with N-nitrosodiethylamine-induced hepatocellular carcinoma at early and advanced stages in male Wistar rats. Mol Med Report 4, 1211–1217, 2011.
   PubMed Web of Science ®Google Scholar
• Salado C, Olaso E, Gallot N, Valcarcel M, Egilegor E, et al.: Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18. J Transl Med 9, 59, 2011.
   Web of Science ®Google Scholar
• Lin HC, Chen YF, Hsu WH, Yang CW, Kao CH, et al. Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model. Cancer Prev Res (Phila) 5, 952–962, 2012.
   PubMed Web of Science ®Google Scholar
• Oi N, Jeong CH, Nadas J, Cho YY, Pugliese A, et al.: Resveratrol, a red wine polyphenol, suppresses pancreatic cancer by inhibiting leukotriene A (4)hydrolase. Cancer Res 70, 9755–9764, 2010.
   PubMed Web of Science ®Google Scholar
• Shankar S, Nall D, Tang SN, Meeker D, Passarini J, et al.: Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial- mesenchymal transitions. Plos One 6, e16530, 2011.
   PubMed Web of Science ®Google Scholar
• Seeni A, Takahashi S, Takeshita K, Tang M, Sugiura S, et al.: Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev 9, 7–14, 2008.
   PubMed Web of Science ®Google Scholar
• Wang TT, Hudson TS, Wang TC, Remsberg CM, Davies NM, et al.: Differential effects of resveratrol on androgenresponsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis 29, 2001–2010, 2008.
   PubMed Web of Science ®Google Scholar
• Dias SJ, Li K, Rimando AM, Dhar S, Mizuno CS, et al.: Trimethoxy-resveratrol and piceatannol administered orally suppress and inhibit tumor formation 686 and growth in prostate cancer xenografts. Prostate 73, 1135–1146, 2013.
   PubMed Web of Science ®Google Scholar
• Li G, Rivas P, Bedolla R, Thapa D, Reddick RL, et al.: Dietary resveratrol prevents development of high-grade prostatic intraepithelial neoplastic lesions: involvement of SIRT1/S6K axis. Cancer Prev Res 6, 27–39, 2013.
   PubMed Web of Science ®Google Scholar
• Li J, Chong T, Wang Z, Chen H, Li H, et al.: A novel anticancer effect of resveratrol: reversal of epithelial mesenchymal transition in prostate cancer cells. Molecular Medicine Reports 10, 1717–1724, 2014.
   PubMed Web of Science ®Google Scholar
• Bhat KP and Pezzuto JM: Cancer chemopreventive activity of resveratrol. Annals of the New York Academy of Sciences 957, 210–229, 2002.
   PubMed Web of Science ®Google Scholar
• Vitrac X, Moni JP, Vercauteren J, Deffieux G, and Me´ rillon JM: Direct liquid chromatography analysis of resveratrol derivatives and flavanonols in wines with absorbance and fluorescence detection. Analytica Chimica Acta 458, 103–110, 2002.
   Web of Science ®Google Scholar
• Hare Y: Green Tea: Health Benefits and Applications. New York: Marcel Dekker, 2001.
   Google Scholar
• Jung YD, Kim MS, Shin BA, Chay KO, Ahn BW, et al.: EGCG, a major component of green tea, inhibits tumor growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer 84, 844–850, 2001.
   PubMed Web of Science ®Google Scholar
• Singh AK, Seth P, Anthony P, Husain MM, Madhavan S, et al.: Green tea constituent epigallocatechin-3-gallate inhibits angiogenic differentiation of human endothelial cells. Arch Biochem Biophys 401, 29–37, 2002.
   PubMed Web of Science ®Google Scholar
• Zhu B, Zhan W, Li Z, Wang Z, He Y, et al.: (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. World J Gastroenterol 13, 1162–1169, 2007.
   PubMed Web of Science ®Google Scholar
• Shen X, Zhang Y, Feng Y, Zhang L, Li J, et al.: Epigallocatechin-3-gallate inhibits cell growth, induces apoptosis and causes S phase arrest in hepatocellular carcinoma by suppressing the AKT pathway. Int J Oncol 44, 791–796, 2014.
   PubMed Web of Science ®Google Scholar
• Delgado L, Fernandes I, González-Manzano S, de Freitas V, Mateus N, aet al.: Anti-proliferative effects of quercetin and catechin metabolites. Food Funct 5, 797–803, 2014.
   PubMed Web of Science ®Google Scholar
• Perabo FGE, Von Low EC, Ellinger J, von Rucker A, Muller SC, et al.: Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer and Prostatic Diseases 11, 6–12, 2008.
   PubMed Web of Science ®Google Scholar
• Lamartiniere CA, Murrill WB, Manzolillo PA, Zhang JX, Barnes S, et al.: Genistein alters the ontogeny of mammary cancer development and protects against mammary cancer in rats. Proc Soc Exp Biol Med 217, 358–364, 1998.
   PubMed Web of Science ®Google Scholar
• Martínez-Montemayor MM, Otero-Franqui E, Martinez J, De La Mota-Peynado A, Cubano LA, et al.: Individual and combined soy isoflavones exert differential effects on metastatic cancer progression. Clin Exp Metastasis 27, 465–480, 2010.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21, 2895–2900, 2001.
   PubMed Web of Science ®Google Scholar
• Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, et al.: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14, 4491–4499, 2008.
   PubMed Web of Science ®Google Scholar
• Moyers SB and Kumar NB: Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr Rev 62, 204–211, 2004.
   PubMed Web of Science ®Google Scholar
• Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, et al.: Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 9, 3312–3319, 2003.
   PubMed Web of Science ®Google Scholar
• Ullmann U, Haller J, Decourt JP, Girault N, Girault J, et al.: A single ascending dose study of epigallocatechin gallate in healthy volunteers. J Int Med Res 31, 88–101, 2003.
   PubMed Web of Science ®Google Scholar
• Chow HH, Cai Y, Alberts DS, Hakim I, Dorr R, et al.: Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev 10, 5–583, 2001.
   Web of Science ®Google Scholar
• Tang SN, Singh C, Nall D, Meeker D, Shankar S, et al.: The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. Journal of Molecular Signaling 5, 1–15, 2010.
   PubMedGoogle Scholar
• Milty KW, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, et al.: Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 77, 875–882, 2003.
   PubMed Web of Science ®Google Scholar
• deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y, et al.: Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology 63, 259–263, 2004.
   PubMed Web of Science ®Google Scholar
• Jarred RA, Keikha M, Dowling C, McPherson SJ, Clare AM, et al.: Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev 11, 1689–1696, 2002.
   PubMed Web of Science ®Google Scholar
• Malhotra A, Nair P, and Dhawan DK: Premature mitochondrial senescence and related ultrastructural changes during lung carcinogenesis modulation by curcumin and resveratrol. Ultrastructural Pathology 36, 179–184, 2012.
   PubMed Web of Science ®Google Scholar
• Tang SN, Singh C, Nall D, Meeker D, Shankar S, et al.: The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. Journal of Molecular Signaling 5, 1–15, 2010.
   PubMedGoogle Scholar
• Mertens-Talcott SU and Percival SS: Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells. Cancer Lett 218, 141–151, 2005.
   PubMed Web of Science ®Google Scholar
• Harper CE, Cook LM, Patel BB, Wang J, Eltoum IA, et al.: Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats. Prostate 69, 1668–1682, 2009.
   PubMed Web of Science ®Google Scholar
• Kim JH, Chen C, and Kong ANT: Resveratrol inhibits genistein-induced multi-drug resistance protein 2 (MRP2) expression in HepG2 cells. Arch Biochem Biophys 512, 160–166, 2011.
   PubMed Web of Science ®Google Scholar
• Amin AR, Wang D, Zhang H, Peng S, Shin HJ, et al.: Enhanced Anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin potential role of p53. The Journal of Biological Chemistry 285, 34557–34565, 2010.
   PubMed Web of Science ®Google Scholar
• Feres G, Salluh JI, Ferreira C, and Soares M: Severe acute tumor lysis syndrome in patients with germ-cell tumors. Indian Journal of Urology 24, 555–557, 2008.
   PubMedGoogle Scholar
• Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev 3, 768–780, 2003.
   Google Scholar
• Davis CD: Nutritional interactions: credentialing of molecular targets for cancer prevention. Experimental Biology and Medicine 232, 176–183, 2007.
   PubMed Web of Science ®Google Scholar
• Ma H, Das T, Pereira S, Yang Z, Zhao M, et al.: Efficacy of dietary antioxidants combined with a chemotherapeutic agent on human colon cancer progression in a fluorescent orthotopic mouse Model. Anticancer Research 29, 2421–2426, 2009.
   PubMed Web of Science ®Google Scholar
• Jung B and Ahmad N: Melatonin in cancer management: progress and promise. Cancer Research 66, 9789–9793, 2006.
   PubMed Web of Science ®Google Scholar
• Yunos NM, Beale P, Yu JQ, and Hu F: Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells. Anticancer Research 31, 1131–1140, 2011.
   PubMed Web of Science ®Google Scholar
• Srimuangwong K, Tocharus C, Chintana PY, Suksamrarn A, and Tocharus J: Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells. World J Gastroenterol 18, 2383–2389, 2011.
   Web of Science ®Google Scholar
• Suganuma M, Okabe S, Kai, Y, Sueoka N, Sueoka E, et al.: Synergistic effects of (-)-epigallocatechin gallate with (-)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res 59, 44–47, 1999.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Lee YJ, Im JH, Won SY, Kim YB, et al.: Synergistic anti-cancer effects of resveratrol and chemotherapeutic agent clofarabine against human malignant mesothelioma MSTO-211H cells. Food Chem Toxicol 52, 61–68, 2013.
   PubMed Web of Science ®Google Scholar
• Mohapatra P, Preet R, Choudhuri M, Choudhuri T, and Kundu CN: 5-fluorouracil increases the chemopreventive potentials of resveratrol through DNA damage and MAPK signaling pathway in human colorectal cancer cells. Oncol Res 19, 311–321, 2011.
   PubMed Web of Science ®Google Scholar
• Kao T, Chung Y, Hou Y, Tsai Y, Chen C, et al.: Effects of ellagic acid on chemosensitivity to 5-fluorouracil in colorectal carcinoma cells. Anticancer Research 32, 4413–4418, 2012.
   PubMed Web of Science ®Google Scholar
• Wang H: Combined effect of docetaxel and cisplatin for non-small cell lung cancer cell lines in vitro. Nagoya J Med Sci 63, 129–137, 2000.
   PubMedGoogle Scholar
• Duarte VM, Han E, Veena MS, Salvado A, Suh JD, et al.: Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKbeta protein of the NFkappaB pathway. Molecular Cancer Therapeutics 9, 2665–2675, 2010.
   PubMed Web of Science ®Google Scholar
• Nautiyal J, Banerjee S, Kanwar SS, Yu Y, Patel BB, et al.: Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. International Journal of Cancer 128, 951–961, 2011.
   PubMed Web of Science ®Google Scholar
• Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, et al.: HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. Cancer Biology and Therapy 12, 837–845, 2011.
   PubMed Web of Science ®Google Scholar
• Sartippour MR, Pietras R, Marquez-Garban DC, Chen HW, Heber D, et al.: The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis 27, 2424–2433, 2006.
   PubMed Web of Science ®Google Scholar
• Stuart MC, Larsen L, and Rosengren RJ: Potential mechanisms for the synergistic cytotoxicity elicited by 4-hydroxytamoxifen and epigallocatechin gallate in MDA-MB-231 cells. Int J Oncol. 30, 1407–1412, 2007.
   PubMed Web of Science ®Google Scholar
• Zhang FY, Du GJ, Zhang L, Zhang CL, Lu WL, et al.: Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein. Pharmaceutical Research 26, 914–925, 2006.
   Web of Science ®Google Scholar
• Fukui M, Yamabe N, and Zhu BT: Resveratrol attenuate the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. Eur J Cancer 46, 1882–1891, 2010.
   PubMed Web of Science ®Google Scholar
• Epelbaum R, Schaffer M, Vizel B, Badmaev V, and Bar-Sela G: Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 62, 1137–1141, 2010.
   PubMed Web of Science ®Google Scholar
• Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, et al.: A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine resistant pancreatic cancer. Cancer Chemother Pharmacol 68, 157–164, 2011.
   PubMed Web of Science ®Google Scholar
• Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, et al.: Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Ann Oncol 23, 688–694, 2012.
   PubMed Web of Science ®Google Scholar
• Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, et al.: Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 25, 669–674, 2007.
   PubMed Web of Science ®Google Scholar
• Robert BM, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, et al.: Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 9, 8–14, 2010.
   PubMed Web of Science ®Google Scholar
• Gupta SC, Kim JH, Prasad S, and Aggarwal BB: Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29, 405–434, 2010.
   PubMed Web of Science ®Google Scholar
• Greco F and Vicent MJ: Combination therapy: opportunities and challenges for polymer-drug conjugate as anticancer nanomedicines. Adv Drug Deliv Rev 61, 1203–1213, 2009.
   PubMed Web of Science ®Google Scholar
• Gandhi NS, Tekade RK, and Chougule MB: Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances. J Control Release 194C, 238–256, 2014.
   Web of Science ®Google Scholar
• Zlotogorski A, Dayan A, Dayan D, Chaushu G, Salo T, et al.: Nutraceuticals as new treatment approaches for oral cancer-I: Curcumin. Oral Oncol 49, 187–191, 2013.
   PubMed Web of Science ®Google Scholar
• Kim JY, Shim G, Choi HW, Park J, Chung SW, et al.: Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex. Biomaterials 33, 4424–4430, 2012.
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, and Wu XY: Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release 116, 275–284, 2006.
   PubMed Web of Science ®Google Scholar
• Shuhendler AJ, Cheung RY, Manias J, Connor A, Rauth AM, et al.: A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res Treat 119, 255–269, 2009.
   PubMed Web of Science ®Google Scholar
• Basu S, Harfouche R, Soni S, Chimote G, Mashelkar RA, et al.: Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc Natl Acad Sci U S A 106, 7957–7961, 2009.
   PubMed Web of Science ®Google Scholar
• Wu J, Lu Y, Lee A, Pan X, Yang X, et al.: Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci 10, 350–357, 2007.
   PubMed Web of Science ®Google Scholar
• Ichiki H, Hamasaki S, Nakasaki M, Ishida S, Yoshikawa A, et al.: Relationship between hyperglycemia and coronary vascular resistance in nondiabetic patients. Int J Cardiol 141, 44–48, 2010.
   PubMed Web of Science ®Google Scholar
• Roy V, La Plant BR, Gross GG, Bane CL, Palmieri FM, and North Central Cancer Treatment Group: Phase II trial of weekly nab (nanoparticle albuminbound)- paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 20, 449–453, 2009.
   PubMed Web of Science ®Google Scholar
• Zucker D, Andriyanov AV, Steiner A, Raviv U, and Barenholz Y. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy. J Control Release 160, 281–289, 2012.
   PubMed Web of Science ®Google Scholar
• Zucker D and Barenholz Y: Optimization of vincristine-topotecan combination–paving the way for improved chemotherapy regimens by nanoliposomes. J Control Release 146, 326–333, 2010.
   PubMed Web of Science ®Google Scholar
• Abe K, Abgrall N, Aihara H, Ajima Y, Albert JB, et al.: The T2K experiment. Nuclear Instruments & Methods in Physics Research Section a-Accelerators Spectrometers Detectors and Associated Equipment 659, 106–135, 2011.
   Web of Science ®Google Scholar
• Kaneshiro TL and Lu ZR: Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials 30, 5660–5666, 2009.
   PubMed Web of Science ®Google Scholar
• Namiki Y, Fuchigami T, Tada N, Kawamura R, Matsunuma S, et al.: Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring. Acc Chem Res 44, 1080–1093, 2011.
   PubMed Web of Science ®Google Scholar
• Liu Y, Miyoshi H, and Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer 120, 2527–2537, 2007.
   PubMed Web of Science ®Google Scholar
• Puri A and Blumenthal R: Polymeric lipid assemblies as novel theranostic tools. Acc Chem Res 44, 1071–1079, 2011.
   PubMed Web of Science ®Google Scholar
• Yang J, Lee CH, Ko HJ, Suh JS, Yoon HG, et al.: Multifunctional magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on breast cancer. Angew Chem Int Ed Engl 46, 8836–8839, 2007.
   PubMed Web of Science ®Google Scholar
• Yu MK, Jeong YY, Park J, Park S, Kim JW, et al.: Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew Chem Int Ed Engl 47, 5362–5365, 2008.
   PubMed Web of Science ®Google Scholar
• Kumar A, Sahoo B, Montpetit A, Behera S, Lockey RF, et al.: Development of hyaluronic acid-Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides. Nanomedicine 3, 132–137, 2007.
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Othman SF, Curtis ET, Bauer NA, Chauhan N, et al.: Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. Int J Nanomedicine 7, 1761–1779, 2012.
   PubMed Web of Science ®Google Scholar
• Shi X, Thomas TP, Myc LA, Kotlyar A, and Baker JR Jr.: Synthesis, characterization, and intracellular uptake of carboxyl-terminated poly (amidoamine) dendrimer-stabilized iron oxide nanoparticles. Phys Chem Chem Phys 9, 5712–5720, 2007.
   PubMed Web of Science ®Google Scholar
• Yuan ZP, Chen LJ, Fan LY, Tang MH, Yang GL, et al.: Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clin Cancer Res 12, 3193–3199, 2006.
   Web of Science ®Google Scholar
• Jain AK, Thanki K, and Jain S. Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: implications on oral Bioavailability, antitumor efficacy, and drug-Induced toxicity. Molecular Pharmaceutics 10, 3459–3574, 2013.
   PubMed Web of Science ®Google Scholar
• Shukla R, Chanda N, Zambre A, Upendran A, Katti K, et al.: Laminin receptor specific therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating prostate cancer. Proc Natl Acad Sci USA 109, 12426–12431, 2012.
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, et al.: Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. Journal of Ovarian Research 3, 11, 2010.
   PubMed Web of Science ®Google Scholar
• Gao J, Feng S, and Guo Y. Nanomedicine against multidrug resistance in cancer treatment. Nanomedicine 7, 465–468, 2012.
   PubMed Web of Science ®Google Scholar
• Wang X, Li Y, Yao H, Ju R, Zhang Y, et al.: The use of mitochondrial targeting resveratol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials 32, 5673–5687, 2011.
   PubMed Web of Science ®Google Scholar
• Sanna V and Sechi M: Nanoparticle therapeutics for prostate cancer treatment. Nanomedicine 8, S31–S36, 2012.
   PubMed Web of Science ®Google Scholar
• Figueiro F, Bernardi A, Frozza RL, Terroso T, Zanotto-Filho A, et al.: Resveratrol-loaded lipid core nanocapsules treatment reduced in vitro and in vivo glioma growth. J Biomedical Nanotechnology 9, 516–526, 2013.
   PubMed Web of Science ®Google Scholar
• Karthikeyan S, Rajendra Prasad N, Ganamani A, and Balamurugan E. Anticancer activity of resveratrol-loaded gelatin nanoparticles on NCI-H460 non-small cell lung cancer cells. Biomedicine & Preventive Nutrition 3, 64–73, 2013.
   Google Scholar
• Bu L, Gan LC, Guo X-Q, Chen FZ, Song Q, et al.: Trans-resveratrol loaded chitosan nanoparticles modified with biotin and avidin to target hepatic carcinoma. Int J Pharm 452, 355–362, 2013.
   PubMed Web of Science ®Google Scholar
• Vergaro V, Lvov YM, and Leporatti S: Halloysite clay nanotubes for resveratrol delivery to cancer cells. Macromol Biosci 12, 1265–1271, 2012.
   PubMed Web of Science ®Google Scholar
• Misra R and Sahoo SK: Coformulation of doxorubicin and curcumin in poly (D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm 8, 852–866, 2011.
   PubMed Web of Science ®Google Scholar
• Yadav S, van Vlerken LE, Little SR, and Amiji MM: Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol 63, 711–722, 2009.
   PubMed Web of Science ®Google Scholar
• Milane L, Duan Z, and Amiji M: Developments of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol Pharm 8, 185–203, 2011.
   PubMed Web of Science ®Google Scholar
• Song XR, Cai Z, Zheng Y, He G, Cui FY, Gong DQ, et al.: Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci 37, 300–305, 2009.
   PubMed Web of Science ®Google Scholar
• Patil Y, Sadhukha T, Ma L, and Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcome tumor drug resistance. J Control Release 136, 21–29, 2009.
   PubMed Web of Science ®Google Scholar
• Mohan A, Narayanan S, Sethuraman S, and Krishnan UM: Novel Resveratrol and 5-fluorouracil coencapsulated in PEGylated nanoliposomes improve chemotherapeutic efficacy of combination against head and neck squamous cell carcinoma. Biomed Res Int 2014, 424–239, 2014.
   Web of Science ®Google Scholar
• Ahn S, Kim D, Kang J, and Lee M: Synergistic effects of 5-fluorouracil (FU) and curcumin on human cervical cancer cells. Korean J Microscopy 4, 229–235, 2010.
   Google Scholar
• Vinod BS, Antony J, Nair HH, Puliyappadamba VT, Saikia M, et al.: Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil. Cell Death and Disease 4, e505, 2013.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Chen Q, Du J, Wang X, Lu Y, et al.: Synergistic effect of combinatorial treatment with curcumin and mitomycin c on the induction of apoptosis of breast cancer cells: a cDNA microarray analysis. Int J Mol Sci 15, 16284–16301, 2014.
   PubMed Web of Science ®Google Scholar
• Sakata M, Ikeda T, Imoto, S, Takeshima K, Enomoto K, et al.: Influence of green tea extract and tamoxifen on murine mammary carcinogenesis and estrogen metabolism. Proc Jpn Cancer Asssoc 54, 128, 1995.
   Google Scholar
• Luo T, Wang J, Yin Y, Hua H, Jing J, et al.: (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Research 12, R8, 2010.
   Web of Science ®Google Scholar
• Daker M, Ahmad M, and Khoo ASB: Quercetin-induced inhibition and synergistic activity with cisplatin – a chemotherapeutic strategy for nasopharyngeal carcinoma cells. Cancer Cell International 12, 34, 2012.
   PubMed Web of Science ®Google Scholar
• Ping SY, Hour TC, Lin SR, and Yu DS. Taxol synergizes with antioxidants in inhibiting hormonal refractory prostate cancer cell growth. Urologic Oncology: Seminars and Original Investigations 28, 170–179, 2010.
   PubMed Web of Science ®Google Scholar
• Zhu H, Cheng H, Ren Y, Liu ZG, Zhang YF, et al.: Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo. Mol Bio Rep 39, 4971–4979, 2012.
   PubMed Web of Science ®Google Scholar
• Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, et al.: Resveratrol, a multi-targeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer 127, 257–268, 2010.
   PubMed Web of Science ®Google Scholar
• Wu S, Sun Z, Yu L, Meng K, Qin X, et al.: Effect of resveratrol and in combination with 5-FU on murine liver cancer. World J Gastroenterol 10, 3048–3052, 2004.
   PubMed Web of Science ®Google Scholar
• Kawada M, Ohno Y, Ri Y, Ikoma T, Yuugetu H, et al.: Anti-tumor effect of gallic acid on LL-2 lung cancer cells transplanted in mice. Anticancer Drugs 12, 847–852, 2001.
   PubMed Web of Science ®Google Scholar
• Shi R, Huang Q, Zhu X, Ong YB, Zhao B, et al.: Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization. Mol Cancer Ther 6, 1338–1347, 2007.
   PubMed Web of Science ®Google Scholar
• Tikoo K, Sane M, and Gupta C. Tannic acid ameliorates doxorubicin-induced cardiotoxicity and potentiates its anti-cancer activity: Potential role of tannins in cancer chemotherapy. Toxicol Appl Pharmacol 25, 191–200, 2011.
   Web of Science ®Google Scholar
• Tang Y, Parmakhtiar B, Simoneau AR, Xie J, Fruehauf J, et al.: Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels. Neoplasia 13, 108–113, 2011.
   PubMed Web of Science ®Google Scholar
• Meiyanto E, Fitriasari A, Hermawan A, Junedi S, and Susidarti RA: The improvement of doxorubicin activity by citrus flavonoid tangeretin through cell cycle modulation and apoptotic induction on breast cancer cell lines. Oriental Pharmacy and Experimental Medicine 11, 183–190, 2011.
   Google Scholar
• Hermawan A, Meiyanto E, and Susidarti DRA: Hesperidin increase cytotoxic effect of doxorubicin in MCF-7 cells. Adam Majalah Farmasi Indonesia 21, 8–17, 2010.
   Google Scholar
• Febriansah R, Putri DDP, Sarmoko S, Nurulita NA, Meiyanto E, et al.: Hesperidin as a preventive resistance agent in MCF-7 breast cancer cells line resistance to doxorubicin. Asian Pac J Trop Biomed 4, 228–233, 2014.
   PubMedGoogle Scholar
• Kallifatidis G, Labsch S, Rausch V, Mattern J, Gladkich J, et al.: Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther 19, 188–195, 2011.
   PubMed Web of Science ®Google Scholar
• Xu Y, Xin Y, Diao Y, Lu C, Fu J, et al.: Synergistic effects of apigenin and paclitaxel on apoptosis of cancer cells. PLoS ONE 6, e29169, 2011.
   PubMed Web of Science ®Google Scholar
• Patil YB, Swaminathan SK, Sadhukha T, Ma L, and Panyam J: The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31, 358–365, 2010.
   PubMed Web of Science ®Google Scholar
• Song XR, Zheng Y, He G, Yang L, Luo YF, et al.: Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma. J Pharm Sci 99, 4874–4879, 2010.
   PubMed Web of Science ®Google Scholar
• Dilnawaz F, Singh A, Mohanty C, and Sahoo SK: Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 31, 3694–3706, 2010.
   PubMed Web of Science ®Google Scholar
• Wiradharma N, Tong YW, and Yang YY: Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect. Biomaterials 30, 3100–3109, 2009.
   PubMed Web of Science ®Google Scholar
• Lammers T, Subr V, Ulbrich K, Peschke P, Huber PE, et al.: Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 30, 3466–3475, 2009.
   PubMed Web of Science ®Google Scholar
• Tekade RK, Dutta T, Tyagi A, Bharti AC, Das BC, et al.: Surface engineered dendrimers for dual drug delivery: a receptor up-regulation and enhanced cancer targeting strategy. J Drug Target 16, 758–772, 2008.
   PubMed Web of Science ®Google Scholar
• Patel NR, Rathi A, Mongayt D, and Torchilin VP: Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using longcirculating liposomes. Int J Pharm 416, 296–299, 2011.
   PubMed Web of Science ®Google Scholar
• Shim G, Han SE, Yu YH, Lee S, Lee HY, et al.: Trilysinoyl leylamidebased cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. J Control Release 155, 60–66, 2011.
   PubMed Web of Science ®Google Scholar
• Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, et al.: In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 33, 129–139, 2009.
   PubMed Web of Science ®Google Scholar
• Batist G, Gelmon KA, Chi KN, Miller WH Jr, Chia SK, et al.: Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res 15, 692–700, 2009.
   PubMed Web of Science ®Google Scholar
• Li X, Lu WL, Liang GW, Ruan GR, Hong HY, et al.: Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice. Eur J Clin Invest 36, 409–418, 2006.
   PubMed Web of Science ®Google Scholar
• Kim JY, Shim G, Choi HW, Park J, Chung SW, et al.: Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex. Biomaterials 33, 4424–4430, 2012.
   PubMed Web of Science ®Google Scholar
• Zhang YF, Wang JC, Bian DY, Zhang X, and Zhang Q. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur J Pharm Biopharm 74, 467–473, 2010.
   PubMed Web of Science ®Google Scholar
• Cosco D, Paolino D, Cilurzo F, Casale F, and Fresta M. Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases. Int J Pharm 422, 229–237, 2012.
   PubMed Web of Science ®Google Scholar